Moccia F, Mazzarello G P, Morra L
DIMI, Cattedra di Terapia Medica, University of Genoa, Italy.
Biomed Pharmacother. 1991;45(9):403-8. doi: 10.1016/0753-3322(91)90004-d.
We have studied the CFU-GM and BFU-E in vitro growth in a neutropenic and anemic patient with Felty's syndrome, either before or one and three months after steroid therapy when neutrophils and erythrocytes returned to normal. Both CFU-GM growth and CSA production were found to be low before therapy, and prednisone was shown to raise them to normal levels. The in vitro growth of BFU-E and the production of BPA by T lymphocytes of the patient were significantly lower than normal when studied before therapy. However, the T lymphocytes incubated in vitro with hydrocortisone regained their ability to stimulate the BFU-E growth. After prednisone therapy both BFU-E growth and BPA production by T lymphocytes returned to normal. Possible pathogenetic mechanisms of impaired granulo- and erythropoiesis in Felty's syndrome are discussed. The in vitro study with hydrocortisone can help to identify steroid-sensitive patients.
我们研究了一位患有费尔蒂综合征的中性粒细胞减少和贫血患者在体外培养的CFU-GM和BFU-E的生长情况,观察时间为激素治疗前以及中性粒细胞和红细胞恢复正常后的1个月及3个月。研究发现,治疗前CFU-GM的生长及CSA的产生均较低,泼尼松可使其升至正常水平。治疗前研究发现,患者的BFU-E体外生长及T淋巴细胞产生BPA的能力显著低于正常水平。然而,体外与氢化可的松共同孵育的T淋巴细胞恢复了刺激BFU-E生长的能力。泼尼松治疗后,T淋巴细胞的BFU-E生长及BPA产生均恢复正常。本文讨论了费尔蒂综合征中粒细胞生成和红细胞生成受损的可能发病机制。氢化可的松的体外研究有助于识别对类固醇敏感的患者。